| Zacks Company Profile for Arcutis Biotherapeutics, Inc. (ARQT : NSDQ) |
|
|
| |
| • Company Description |
| Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
Number of Employees: 354 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $23.90 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,519,056 shares |
| Shares Outstanding: 125.69 (millions) |
| Market Capitalization: $3,004.04 (millions) |
| Beta: 1.50 |
| 52 Week High: $31.77 |
| 52 Week Low: $16.57 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-7.79% |
-7.38% |
| 12 Week |
-6.57% |
-8.56% |
| Year To Date |
-17.70% |
-27.01% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
3027 TOWNSGATE ROAD SUITE 300
-
WESTLAKE VILLAGE,CA 91361
USA |
ph: 805-418-5006
fax: - |
ir@arcutis.com |
http://www.arcutis.com |
|
|
| |
| • General Corporate Information |
Officers
Todd Franklin Watanabe - President; Chief Executive Officer and Director
Keith R. Leonard - Director; Chairman
Latha Vairavan - Chief Financial Officer
Terrie Curran - Director
Halley E. Gilbert - Director
|
|
Peer Information
Arcutis Biotherapeutics, Inc. (CORR.)
Arcutis Biotherapeutics, Inc. (RSPI)
Arcutis Biotherapeutics, Inc. (CGXP)
Arcutis Biotherapeutics, Inc. (BGEN)
Arcutis Biotherapeutics, Inc. (GTBP)
Arcutis Biotherapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03969K108
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 10/27/26
|
|
Share - Related Items
Shares Outstanding: 125.69
Most Recent Split Date: (:1)
Beta: 1.50
Market Capitalization: $3,004.04 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.17 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $0.40 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 10/27/26 |
|
|
|
| |
